Aliases & Classifications for Rosacea

MalaCards integrated aliases for Rosacea:

Name: Rosacea 12 25 43 44 15 63 17 72 33
Erythematotelangiectatic Rosacea 25
Papulopustular Rosacea 25
Granulomatous Rosacea 25
Acne, Erythematosa 12
Phymatous Rosacea 25
Ocular Rosacea 25
Acne Roscea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8881
ICD9CM 35 695.3
MeSH 44 D012393
NCIt 50 C97136
SNOMED-CT 68 1612004
ICD10 33 L71 L71.9
UMLS 72 C0035854

Summaries for Rosacea

Genetics Home Reference : 25 Rosacea is a long-lasting (chronic) skin disease that affects the face, primarily the forehead, nose, cheeks, and chin. The signs and symptoms of rosacea vary, and they may come and go or change over time. There are three main types of rosacea, categorized by their primary signs and symptoms. Erythematotelangiectatic rosacea causes skin redness and warmth (flushing) and visible clusters of blood vessels (telangiectasia). Papulopustular rosacea causes skin redness, swelling, and pus-filled bumps called pustules. Phymatous rosacea is characterized by thickened skin on the face and an enlarged, bulbous nose (rhinophyma). People with rosacea may feel itching, stinging, or burning sensations in affected areas. Often, the disorder affects the eyes, causing abnormal inflammation of the eyelids and eyes (ocular rosacea). This inflammation can cause dryness, redness, and irritation of the eyes and may affect vision.

MalaCards based summary : Rosacea, also known as erythematotelangiectatic rosacea, is related to keratitis, hereditary and pyoderma, and has symptoms including pruritus and exanthema. An important gene associated with Rosacea is CAMP (Cathelicidin Antimicrobial Peptide), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Isotretinoin and Hydroquinone have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

MedlinePlus : 43 Rosacea is a long-term disease that affects your skin and sometimes your eyes. It causes redness and pimples. Rosacea is most common in women and people with fair skin. It most often affects middle-aged and older adults. In most cases, rosacea only affects the face. Symptoms can include Frequent redness of the face, or flushing Small, red lines under the skin Acne A swollen nose Thick skin, usually on the forehead, chin, and cheeks Red, dry, itchy eyes and sometimes vision problems No one knows what causes rosacea. You may be more likely to have it if you blush a lot or if rosacea runs in your family. Rosacea is not dangerous. There is no cure, but treatments can help. They include medicines and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

PubMed Health : 63 About rosacea: Red patches of skin on your face, and tiny visible blood vessels and spots – these can be quite common symptoms. They may be caused by rosacea, a common facial skin inflammation. Skin diseases can be difficult to cope with, and they often affect people’s self-confidence and wellbeing. But if you have rosacea, there is a lot you can do on your own.

Wikipedia : 75 Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples,... more...

Related Diseases for Rosacea

Diseases related to Rosacea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 533)
# Related Disease Score Top Affiliating Genes
1 keratitis, hereditary 31.3 VEGFA TLR2 MMP9
2 pyoderma 30.8 TNF MMP9 CXCL8
3 dermatitis, atopic 30.8 TNF CXCL8 CAMP
4 contact dermatitis 30.6 TNF IL6 CXCL8
5 colitis 30.4 TNF IL6 CXCL8
6 opisthorchiasis 30.0 TNF CXCL8
7 exanthem 30.0 TNF IL6 CRP
8 pulmonary tuberculosis 30.0 VDR TNF TLR2
9 glossitis 29.9 TNF IL6
10 mycobacterium tuberculosis 1 29.9 VDR TNF TLR2
11 fungal keratitis 29.8 TLR2 MMP9 MMP8
12 purpura 29.6 TNF IL6 CRP
13 ulcerative colitis 29.4 TNF IL6 CXCL8 CRP
14 arthritis 29.3 TNF MMP9 IL6 CXCL8
15 psoriatic arthritis 29.3 TNF IL6 CRP
16 atherosclerosis susceptibility 29.0 TNF IL6 CRP
17 inflammatory bowel disease 29.0 TNF TLR2 IL6 CXCL8 CRP
18 vascular disease 28.7 VEGFA TNF MMP9 IL6 CRP
19 chlamydia 28.6 TNF TLR2 IL6 CXCL8 CRP
20 myeloma, multiple 28.3 VEGFA TNF IL6 CXCL8 CRP
21 gastrointestinal system disease 28.2 VEGFA TNF MMP9 IL6 CXCL8 CRP
22 bacterial infectious disease 27.9 TNF TLR2 IL6 CXCL8 CRP CAMP
23 proteasome-associated autoinflammatory syndrome 1 27.7 TNF TLR2 MMP9 IL6 CXCL8 CRP
24 rheumatoid arthritis 27.3 VEGFA TNF TLR2 MMP9 IL6 CXCL8
25 periodontitis 27.0 TNF TLR2 MMP9 MMP8 IL6 CXCL8
26 granulomatous rosacea 12.8
27 rosacea conjunctivitis 12.3
28 blepharitis 11.6
29 neurofibromatosis, type ii 11.0
30 telangiectasis 10.8
31 skin disease 10.8
32 dermatitis 10.7
33 mycobacterium chelonae 10.6 TLR2 CXCL8
34 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.6
35 angiokeratoma circumscriptum 10.6 VEGFA MMP9
36 mycobacterium kansasii 10.5 TLR2 CXCL8
37 neurosyphilis 10.5 TLR2 CXCL8
38 exudative glomerulonephritis 10.5 TNF CXCL8
39 facial dermatosis 10.5
40 kashin-beck disease 10.5 VEGFA TNF
41 vibratory urticaria 10.5 MMP9 CXCL8
42 trench fever 10.5 TNF TLR2
43 adult dermatomyositis 10.5 VDR TNF
44 adamantinous craniopharyngioma 10.5 VEGFA MMP9
45 autoimmune inner ear disease 10.5 TNF MMP9
46 tungiasis 10.4 TNF CXCL8
47 sick building syndrome 10.4 VEGFA MMP9
48 recurrent corneal erosion 10.4 IL6 CXCL8
49 bagassosis 10.4 IL6 CXCL8
50 ischemic colitis 10.4 VEGFA MMP9

Graphical network of the top 20 diseases related to Rosacea:



Diseases related to Rosacea

Symptoms & Phenotypes for Rosacea

UMLS symptoms related to Rosacea:


pruritus, exanthema

MGI Mouse Phenotypes related to Rosacea:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 CGA CRP GTF2IRD1 IL6 MMP8 MMP9
2 cardiovascular system MP:0005385 10.15 CRP GTF2IRD1 IL6 MMP9 PTGDR TLR2
3 immune system MP:0005387 10.1 CAMP CRP IL6 MMP8 MMP9 PTGDR
4 hematopoietic system MP:0005397 10.06 CAMP IL6 MMP9 PTGDR TLR2 TNF
5 integument MP:0010771 9.97 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
6 digestive/alimentary MP:0005381 9.95 IL6 MMP9 TLR2 TNF VDR VEGFA
7 muscle MP:0005369 9.92 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
8 nervous system MP:0003631 9.81 CGA GTF2IRD1 IL6 MMP9 PTGDR TLR2
9 neoplasm MP:0002006 9.8 GTF2IRD1 IL6 MMP8 MMP9 TLR2 TNF
10 respiratory system MP:0005388 9.5 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
11 skeleton MP:0005390 9.17 GTF2IRD1 IL6 MMP9 TLR2 TNF VDR

Drugs & Therapeutics for Rosacea

PubMed Health treatment related to Rosacea: 63

There are a lot of creams, lotions and gels recommended for the treatment of rosacea. Creams and gels with either azelaic acid or the antibiotic metronidazole in them are used most commonly. Antibiotics can also be taken as tablets, but then the entire body is affected.

Drugs for Rosacea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
2
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
3
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
4
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
5
Metronidazole Approved Phase 4 443-48-1 4173
6
Azelaic acid Approved Phase 4 123-99-9 2266
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Adapalene Approved Phase 4 106685-40-9 60164
9
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
10
Phenylephrine Approved Phase 4 59-42-7 6041
11
Ephedrine Approved Phase 4 299-42-3 9294
12
Pseudoephedrine Approved Phase 4 90-82-4 7028
13
Sulfacetamide Approved Phase 4 144-80-9 5320
14
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
15
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
16
Aminolevulinic acid Approved Phase 4 106-60-5 137
17
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
18 Keratolytic Agents Phase 4
19 Antioxidants Phase 4
20 Radiation-Protective Agents Phase 4
21 Salicylates Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Analgesics Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Immunosuppressive Agents Phase 4
27 Immunologic Factors Phase 4
28 Antifungal Agents Phase 4
29 Cyclosporins Phase 4
30 Calcineurin Inhibitors Phase 4
31 Ophthalmic Solutions Phase 4
32 Respiratory System Agents Phase 4
33 Adapalene, Benzoyl Peroxide Drug Combination Phase 4
34 Adrenergic Agonists Phase 4
35 Adrenergic alpha-2 Receptor Agonists Phase 4
36 Adrenergic alpha-Agonists Phase 4
37 Brimonidine Tartrate Phase 4 70359-46-5
38 Cardiotonic Agents Phase 4
39 Sympathomimetics Phase 4
40 Nasal Decongestants Phase 4
41 Protective Agents Phase 4
42 Mydriatics Phase 4
43 Vasoconstrictor Agents Phase 4
44 Autonomic Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Lubricant Eye Drops Phase 4
47 Anti-Allergic Agents Phase 4
48 Photosensitizing Agents Phase 4
49
Oxytetracycline Approved, Investigational, Vet_approved Phase 2, Phase 3 79-57-2 5280972 54715139
50
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea- a Prospective Study Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
2 Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma Unknown status NCT00927771 Phase 4 azelaic acid gel;hydroquinone cream
3 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
4 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed NCT01872715 Phase 4 Oracea
5 A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea Completed NCT00417937 Phase 4 azelaic acid 15% gel;azelaic acid 15% gel
6 Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea Completed NCT00348335 Phase 4 Cyclosporine 0.05%;Ocular lubricant
7 Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence Completed NCT03418610 Phase 4 Azelaic Acid foam 15%
8 A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules Completed NCT01308619 Phase 4 Doxycycline
9 An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea Completed NCT00855595 Phase 4 Azelaic acid (Finacea, BAY39-6251);Metronidazole (Metrogel);Doxycycline (Oracea)
10 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea Completed NCT01426269 Phase 4 Doxycycline;Metronidazole;Placebo
11 Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females Completed NCT01387048 Phase 4 skinoren;differin;skinoren
12 MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study) Completed NCT02249065 Phase 4 Brimonidine
13 Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Completed NCT02147691 Phase 4 Azelaic acid 15%;Brimonidine 0.33%
14 Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea Completed NCT02616250 Phase 4 Brimonidine 0.33% gel (Br);Ivermectin 1% cream (IVM)
15 Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea Completed NCT03380390 Phase 4 Oxymetazoline HCL 1.0% Cream
16 Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea Completed NCT00495313 Phase 4 doxycycline;doxycycline
17 A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea Completed NCT00892281 Phase 4 doxycycline (Oracea®) 40 mg modified release as monotherapy;doxycycline (Oracea®) 40 mg modified release as add-on therapy
18 Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea Completed NCT03048058 Phase 4 brimonidine topical gel 0.33% & survey;brimonidine topical gel 0.33% & SOC
19 MetroGel 1% Hydration Study: A Kinetic Regression Study Completed NCT00436527 Phase 4 Metronidazole gel 1%
20 Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
21 Topical Brimonidine Reduces IPL-induced Erythema Without Affecting Efficacy: a Randomized Controlled Trial in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
22 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
23 Efficacy Comparison of Ivermectin 1% Topical Cream Associated With Doxycycline 40 mg Modified Release (MR) Capsules Versus Ivermectin 1% Topical Cream Associated With Placebo in the Treatment of Severe Rosacea Active, not recruiting NCT03075891 Phase 4 Ivermectin 1% cream;Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
24 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
25 a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis Unknown status NCT02036229 Phase 3 ivermectin cream 0.5%
26 The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
27 Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn Unknown status NCT01886560 Phase 2, Phase 3 Doxycycline;Placebo
28 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea Completed NCT02840461 Phase 3 Ivermectin Cream, 1%;Placebo/Vehicle cream
29 A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension Completed NCT02547441 Phase 3 CLS001 (Omiganan);Vehicle
30 A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period Completed NCT02576860 Phase 3 CLS001 (Omiganan);Vehicle
31 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea Completed NCT01555463 Phase 3 Azelaic acid foam, 15% (BAY39-6251);Vehicle foam
32 A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea Completed NCT02576847 Phase 3 Omiganan
33 A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11 and 12) Completed NCT03142451 Phase 3 FMX-103
34 A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Completed NCT01494467 Phase 3 CD5024;Azelaic acid 15% Gel
35 Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period. Completed NCT01493947 Phase 3 Ivermectin 1% cream;Metronidazole 0.75% cream
36 A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Completed NCT01493687 Phase 3 CD5024;Azelaic acid 15% Gel
37 An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13) Completed NCT03276936 Phase 3 FMX103 1.5%
38 A Multi-center, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Metronidazole Gel 1%, to Metrogel® (Metronidazole Gel) 1% in the Treatment of Rosacea Completed NCT02393937 Phase 3 Reference: Metronidazole Gel 1%;Test: Metronidazole Gel 1%;Placebo Gel
39 A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks Completed NCT00823901 Phase 2, Phase 3 Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel;Placebo gel
40 The Effect of Azelaic Acid (Financea Gel 15%) on Demodex Folliculorum Counts in Adult Subjects With Mild to Moderate Papulopustular Rosacea Completed NCT03035955 Phase 2, Phase 3 Azelaic acid
41 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed NCT02385240 Phase 3 Brimonidine Topical Gel, 0.33 percent (Perrigo);Brimonidine Topical Gel, 0.33 percent (Reference);Placebo gel
42 A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea Completed NCT00126399 Phase 3 doxycycline
43 Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT03352323 Phase 3 Oxymetazoline
44 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed NCT02800148 Phase 3 Azelaic acid foam;Azelaic acid foam;Azelaic acid foam - Placebo
45 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed NCT02795117 Phase 3 Ivermectin;Ivermectin (reference);Placebo
46 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea Completed NCT00041977 Phase 3 doxycycline hyclate 20 mg twice daily
47 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
48 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
49 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
50 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0444 Gel Completed NCT01016782 Phase 3 0444

Search NIH Clinical Center for Rosacea

Inferred drug relations via UMLS 72 / NDF-RT 51 :


azelaic acid
Benzoyl Peroxide
Ciclosporin
Colloid sulfur
Cortisone acetate
Dexamethasone
Doxycycline
Isotretinoin
Ivermectin
Loteprednol
Loteprednol
loteprednol etabonate
Methylprednisolone
Metronidazole
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
Prednisolone
resorcinol
RESORCINOL PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
Tetracycline

Cochrane evidence based reviews: rosacea

Genetic Tests for Rosacea

Anatomical Context for Rosacea

MalaCards organs/tissues related to Rosacea:

41
Skin, Eye, Testes, Liver, Small Intestine, Endothelial, Bone

Publications for Rosacea

Articles related to Rosacea:

(show top 50) (show all 2966)
# Title Authors PMID Year
1
A comment on Helicobacter pylori and rosacea. 38 17
31251009 2019
2
Concerns and Treatment Satisfaction in Patients Being Treated With Azelaic Acid Foam for Rosacea 38 17
31013011 2019
3
Acne and Rosacea: Special Considerations in the Treatment of Patients With Latin American Ancestry 38 17
30909359 2019
4
Clinical and erythema-directed imaging evaluation of papulo-pustular rosacea with topical ivermectin: a 32 weeks duration study. 38
30663445 2019
5
Artemisinin, a potential option to inhibit inflammation and angiogenesis in rosacea. 38
31387196 2019
6
Photodynamic Therapy Assay. 38
31392587 2019
7
Targeting the gut-skin axis - probiotics as new tools for skin disorder management? 38
31386766 2019
8
A Cross-sectional Study of Rosacea and Risk Factors in Women with Frontal Fibrosing Alopecia. 38
31408181 2019
9
New Insight in Noninvasive Rejuvenation: The Role of a Rhodamine-Intense Pulsed Light System. 38
31381488 2019
10
Itch in Elderly People: A Cross-sectional Study. 38
31384955 2019
11
The Role of IL-17 in Papulopustular Rosacea and Future Directions. 38
31402691 2019
12
The relationship between inflammatory bowel disease and rosacea over the lifespan: A meta-analysis. 38
30389397 2019
13
[Rosacea - manifestations and treatment options]. 38
31429390 2019
14
Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel. 38
31392722 2019
15
Global rosacea treatment guidelines and expert consensus points: The differences. 38
30809947 2019
16
Rosacea: Relative risk versus absolute risk of malignant comorbidities. 38
30654083 2019
17
Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study. 38
31182382 2019
18
Image Gallery: Wandering Demodex mite in vivo under ultraviolet dermoscopy of rosacea. 38
31432494 2019
19
Comparative efficacy of short-pulsed intense pulsed light and pulsed dye laser to treat rosacea. 38
30285506 2019
20
Skin-homing T-cell responses associated with Demodex infestation and rosacea. 38
31125450 2019
21
Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes. 38
31132668 2019
22
Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial. 38
31394131 2019
23
Evaluation of the efficacy and tolerance of artemether emulsion for the treatment of papulopustular rosacea: a randomized pilot study. 38
31017492 2019
24
Difference in vasoconstrictors: oxymetazoline vs. brimonidine. 38
31294643 2019
25
Potential association between rosacea and cancer: A study in a medical center in southern China. 38
31120152 2019
26
Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases. 38
31004811 2019
27
Dermatoses in parkinsonism: the importance of multidisciplinary follow-up. 38
31340306 2019
28
Severe Type of Minocycline-Induced Hyperpigmentation Mimicking Peripheral Arterial Occlusive Disease in a Bullous Pemphigoid Patient. 38
31315305 2019
29
A new superficial needle-scraping method for assessing Demodex density in papulopustular rosacea. 38
31343825 2019
30
Dermatologic Problems Commonly Seen by the Allergist/Immunologist. 38
31351991 2019
31
[Acne rosacea-a pedigree with ten cases]. 38
31302927 2019
32
Acne and rosacea: What's new for treatment? 38
31294907 2019
33
Patient-focused Solutions in Rosacea Management: Treatment Challenges in Special Patient Groups 38
31329380 2019
34
Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. 38
30585305 2019
35
Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea. 38
30727789 2019
36
Treatment of granulomatous rosacea with chromophore gel-assisted phototherapy. 38
30854732 2019
37
Rosacea fulminans: two case reports and review of the literature. 38
31169436 2019
38
New evidence but still unmet medical needs in rosacea treatment. 38
31259410 2019
39
Skin diseases are more common than we think: screening results of an unreferred population at the Munich Oktoberfest. 38
30891839 2019
40
Treatment of Rhinophyma With Surgical Excision and Amniotic Membrane. 38
31299768 2019
41
A Prunus persica genome-wide RNA-seq approach uncovers major differences in the transcriptome among chilling injury sensitive and non-sensitive varieties. 38
30203620 2019
42
Risk factors associated with frontal fibrosing alopecia: a multicentre case-control study. 38
30259544 2019
43
Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. 38
30240779 2019
44
Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS). 38
31360284 2019
45
What Is PFE? It May Just Be Time You Found Out.... 38
31251541 2019
46
Systemic comorbidities associated with rosacea: a multicentric retrospective observational study. 38
30575019 2019
47
A Case Report of Fulminant Type 1 Diabetes Mellitus Caused by Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Iodine-Induced Thyrotoxicosis. 38
30937841 2019
48
Rosacea associated with dupilumab therapy. 38
31132923 2019
49
Rosacea fulminans - coincidence of the disease with inflammatory bowel disease. 38
30801824 2019
50
Nested Polymerase Chain Reaction and Cutaneous Tuberculosis. 38
30531542 2019

Variations for Rosacea

Expression for Rosacea

Search GEO for disease gene expression data for Rosacea.

Pathways for Rosacea

Pathways related to Rosacea according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 VEGFA TNF TLR2 MMP9 MMP8 IL6
2
Show member pathways
12.99 TNF TLR2 IL6 CXCL8 CAMP
3
Show member pathways
12.84 VEGFA TNF TLR2 MMP9 IL6 CXCL8
4
Show member pathways
12.79 VEGFA TNF IL6 CXCL8 CGA
5 12.23 VEGFA TNF TLR2 MMP9
6
Show member pathways
12.23 TNF TLR2 MMP9 IL6 CXCL8
7
Show member pathways
12.19 TNF TLR2 IL6 CXCL8
8
Show member pathways
12.14 TNF TLR2 IL6 CXCL8
9 12.11 VDR TNF TLR2 IL6 CAMP
10
Show member pathways
12.1 TNF TLR2 IL6 CXCL8
11 12.09 VEGFA TNF IL6 CXCL8
12 12.02 VEGFA TNF TLR2 MMP9 IL6
13 12 VEGFA TNF MMP9
14
Show member pathways
11.97 TNF TLR2 IL6
15
Show member pathways
11.95 TNF TLR2 MMP9 IL6
16 11.92 TNF MMP9 IL6 CXCL8
17 11.89 TNF MMP9 IL6
18
Show member pathways
11.83 TNF MMP9 MMP8
19 11.83 VEGFA TNF IL6 CXCL8
20 11.82 TNF TLR2 IL6 CXCL8
21 11.74 IL6 CXCL8 CGA
22 11.71 VEGFA TNF MMP9 IL6 CXCL8
23 11.7 TNF IL6 CXCL8
24 11.68 VEGFA MMP9 CXCL8
25 11.66 TNF MMP9 IL6
26 11.62 MMP9 IL6 CXCL8
27 11.58 TNF MMP9 IL6 CXCL8
28 11.57 VEGFA PTGDR MMP9
29 11.52 VEGFA TNF TLR2 IL6 CXCL8
30 11.5 VEGFA IL6 CXCL8
31 11.48 TNF TLR2 IL6 CXCL8
32 11.47 TNF IL6 CXCL8
33 11.46 TNF MMP9 IL6
34 11.36 TNF TLR2 IL6 CXCL8
35 11.28 VDR TNF IL6 CGA
36 11.27 MMP9 IL6 CXCL8
37 11.02 TNF IL6
38 10.82 VDR TNF
39
Show member pathways
10.82 VEGFA TNF MMP9 IL6 CXCL8
40 10.54 TNF IL6 CXCL8 CRP

GO Terms for Rosacea

Cellular components related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 VEGFA TNF MMP9 MMP8 IL6 CXCL8
2 tertiary granule lumen GO:1904724 9.33 MMP9 MMP8 CAMP
3 extracellular space GO:0005615 9.28 VEGFA TNF MMP9 MMP8 IL6 CXCL8

Biological processes related to Rosacea according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 VDR TLR2 IL6 CXCL8
2 cytokine-mediated signaling pathway GO:0019221 9.83 VEGFA TNF MMP9 IL6 CXCL8
3 positive regulation of angiogenesis GO:0045766 9.8 VEGFA CXCL8 CAMP
4 inflammatory response GO:0006954 9.8 TNF TLR2 PTGDR IL6 CXCL8 CRP
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.79 TNF TLR2 IL6
6 defense response GO:0006952 9.79 TNF CXCL8 CAMP
7 cellular response to lipopolysaccharide GO:0071222 9.78 TNF IL6 CXCL8 CAMP
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.72 VEGFA TNF IL6
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.69 TNF TLR2 MMP8
10 positive regulation of interleukin-6 production GO:0032755 9.67 TNF TLR2 MMP8 IL6
11 microglial cell activation GO:0001774 9.61 TNF TLR2
12 embryonic digestive tract development GO:0048566 9.6 TNF CXCL8
13 positive regulation of glial cell proliferation GO:0060252 9.59 TNF IL6
14 macrophage differentiation GO:0030225 9.58 VEGFA MMP9
15 negative regulation of growth of symbiont in host GO:0044130 9.58 TNF CAMP
16 positive regulation of chemokine production GO:0032722 9.58 TNF TLR2 IL6
17 induction of positive chemotaxis GO:0050930 9.57 VEGFA CXCL8
18 response to molecule of bacterial origin GO:0002237 9.56 TLR2 CXCL8
19 regulation of neuroinflammatory response GO:0150077 9.52 MMP9 MMP8
20 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
21 defense response to Gram-positive bacterium GO:0050830 9.35 TNF TLR2 IL6 CRP CAMP
22 positive regulation of neuroinflammatory response GO:0150078 9.33 TNF MMP8 IL6
23 regulation of signaling receptor activity GO:0010469 9.19 CGA
24 positive regulation of gene expression GO:0010628 9.17 VEGFA VDR TNF TLR2 MMP8 IL6
25 regulation of microglial cell activation GO:1903978 9.16 MMP8
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 VEGFA VDR TNF TLR2 IL6 CGA

Molecular functions related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 VEGFA TNF IL6 CXCL8

Sources for Rosacea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....